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Lipid emulsions in parenteral nutrition:  
does one size fits all?
Lipids are essential components of a healthy diet. This is not simply 
because some fatty acids cannot be synthesised by human cells 
and need to be supplied by the diet to prevent clinically relevant 
deficiencies.1 Lipids also represent an energy-dense source, and 
their hydrophobic properties are also critical for the metabolic 
efficiency of body composition. In the latter regard, cell membranes 
are largely made by lipids, which are important in maintaining 
compartamentalisation and cellular integrity. Lipids are also 
metabolically active, since they serve as the skeleton upon which 
many hormones are synthesised and influence human metabolism 
per se. Finally, lipids are thought to have also contributed to the 
evolution of the human race by serving as a metabolic signal during 
periods of food availability, thereby triggering the onset of a metabolic 
milieu favouring energy intake and storage of excess energy as fat 
depots.2 Therefore, it should not be surprising that the inclusion 
of lipid emulsions is recommended when providing PN to patients 
unable to meet their protein and energy needs via the oral and enteral 
route.3 Indeed, if we consider artificial nutrition as a tool to replace 
oral diet when the latter is not feasible, it seems unreasonable to 
exclude lipids and the question arises as to whether we adopt that 
approach when advising a patient who could eat. Nevertheless, lipid 
emulsions are frequently not considered when prescribing PN and 
the practice may be related to to concerns regarding their potential 
toxicity, although it is now clear that their use according to the 
existing guidelines provides more benefits than harm.
Metabolic effects of lipid emulsions
One gram of lipids provides approximately 9 Kcal. In this regard, lipid 
emulsions represent an efficient energy source, and contribute to 
reduce the potential toxicity associated with glucose-based PN and 
hyperglycaemia.1,4,5 Lipids are also known to directly influence the 
inflammatory and immune responses. This effect is mostly related to 
the specific biochemical structure of fatty acids, and therefore it may 
vary according to the different composition of lipid emulsions used in 
PN. It is important to note that commercially available lipid emulsions 
differ in their fatty acid compositions, and may exert different 
modulations of inflammatory and immune responses. Therefore, 
they should be prescribed according to the metabolic profile of the 
patient, in order to accelerate healing and recovery.
Fatty acids are classified according different classes. The omega 
nomenclature classifies unsaturated fatty acids according to the 
distance, in carbon atoms, of the first double bond from the omega end 
of the carbon chain. The first double bond in position 3 characterises 
omega-3 fatty acids (i.e. α-linolenic acid). Omega-6 fatty acids (i.e. 
linoleic acid) have the first double bond 6 carbons from the omega 
end. Omega-9 fatty acids (i.e. oleic acid) are characterised by the 
first double bond being in position 9. Although apparently minimally 
relevant, the position of the double bond significantly influences the 
metabolic effects of lipids.
The most relevant omega-3 fatty acids in clinical nutrition are 
polyunsaturated fatty acids found in plants (i.e. α-linolenic acid) 
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and fish oil [i.e. eicosapentaenoic acid (EPA), docosahexanoic acid 
(DHA)]. Omega-6 fatty acids are the characterising polyunsaturated 
fatty acids found in soybean oil (i.e. linoleic acid) and in fats of 
animal origin. Oleic acid is a monounsaturated fatty acid, which is 
the primary omega-9 fatty acid found in olive oil.
Oxidative stress
The possibility to fully oxidise glucose via aerobic glycolysis represents 
one of the major steps contributing to the evolution of species from 
primordial cells into multicellular organisms. On the other hand, 
respiration, primarily within mitochondria, is a major source of 
reactive oxygen species (ROS). ROS are highly active molecules, 
which act as pro-oxidant.6 By damaging DNA and proteins, they 
contribute to killing invading microbes and inducing inflammation, 
but when produced in excess and not counterbalanced, they induce 
cell damage and apoptosis. Therefore, pro-oxidant effects of ROS 
must be counterbalanced by a series of natural antioxidants, including 
vitamins C and E, glutathione and other such nutrients.6 Imbalance 
in the equilibrium between ROS production and antioxidant systems 
leads to oxidative stress.6 Oxidative stress may result either because 
of an overproduction of ROS or because of the insufficiency/depletion 
of antioxidant systems. The development of oxidative stress is 
clinically relevant since it is thought to contribute to organ failure.7 
Indeed, oxidative stress is associated with injury to major organs 
and systems, since it exerts adverse cardiac,8 neurologic,9 renal,10 
pulmonary11 and haematologic12 effects.
Lipid peroxidation is a determinant of oxidative stress.13 Omega-6 
and omega-3 fatty acids are preferential targets for free radical 
attack and lipid peroxidation because of their multiple double 
bonds,14 and the hydroperoxide formed may oxidise proteins and 
DNA. On the other hand, the single double bond characterising 
omega-9 fatty acids makes them less prone to lipid peroxidation. 
In-vitro studies have shown that the production of ROS, a marker 
of oxidative stress, is influenced by the type of fatty acids, being 
higher when polyunsaturated fatty acids are used as substrate 
when compared with monounsaturated fatty acids.15,16 The clinical 
relevance of this differential influence on oxidative stress still needs 
to be completely elucidated. However, Goulet et al. showed that VLDL 
and LDL peroxidation in paediatric patients receiving long-term PN 
was reduced when lipid emulsions rich in omega-9 fatty acids vs 
omega-6 fatty acids were used.17
Inflammatory and immune response 
Fatty acids influence the inflammatory and immune response by 
their incorporation into cell membranes, and thus modulating gene 
expression, membrane fluidity and exposure of receptors on the cell 
surface.1 Omega-3 and omega-6 fatty acids may compete for the 
same enzymes for metabolism in a state of enzyme saturation.1 
The products formed from omega-3 fatty acids (i.e. the odd-series 
eicosanoids) are typically less potent mediators of inflammation 
than those formed from omega-6 fatty acids (i.e. the even-series 
eicosanoids), whereas the metabolism of omega-9 fatty acids does 
not produce eicosanoids.1 The inflammatory response is generally an 
adaptive, beneficial response to trauma or illness and interference 
with the normal host inflammatory response may prove detrimental 
in some patients.18 However, it may be beneficial to modulate an 
exaggerated inflammatory response (i.e. as seen with sepsis). 
Likewise, a chronic pro-inflammatory state (i.e. in patients receiving 
long-term PN) may have adverse effects.
Omega-6 fatty acids have dose-dependent immunosuppressive 
effects. In vitro and in vivo evidence indicates that omega-6 fatty 
acids lead to impairment of neutrophil chemotaxis and phagocytosis19 
lymphocyte proliferation and reactivity,20 natural killer (NK) and 
lymphokine-activated killer cell activities21 as well as monocyte 
chemotaxis and proliferation.22 Furthermore, administration of 
omega-6 polyunsaturated fatty acids has been associated with 
prolonged graft survival in animal transplant models23 When given 
in excess, omega-3 fatty acids may have an immunosuppressive 
effect,24 but perhaps the ratio of omega-6 to omega-3 may be 
important in determining the extent of immunosuppression.25 
Omega-3 polyunsaturated fatty acids are also generally regarded as 
anti-inflammatory. In addition to shifting eicosanoid production toward 
those that are less pro-inflammatory, omega-3 polyunsaturated fatty 
acids may suppress inflammation through production of resolvins and 
protectins (which facilitate resolution of inflammation) and through 
regulation of gene expression (i.e. cytokine expression).1 Clinical 
studies have demonstrated favorable changes in the fatty acid and 
eicosanoid profiles of surgical patients receiving fish oil-containing 
versus soybean oil-based lipid emulsions.26 Similar benefits have 
been observed in septic patients in a study which used fish oil alone 
at a dose that was more than 3 times greater than the recommended 
maximum dose.27 In contrast, omega-9 monounsaturated fatty acids 
have shown limited to no impact on lymphocyte proliferation or NK 
cell activity in vitro or ex vivo. 28,29
Lipid emulsions in clinical practice
For many years, PN has been considered as a life saving and effective 
tool to feed patients who cannot eat. In this light, lipids were regarded 
as a mere energy-dense source. It is now clear that many nutrients, 
and specifically amino acids (i.e. glutamine, leucine, arginine,) 
and lipids, do exert metabolic effects. It is therefore reasonable to 
propose that such essential nutrients as lipids should be prescribed 
to patients in order to nutritionally support them and influence their 
metabolism, in order to facilitate healing and recovery. Actually, many 
examples can be taken from animal biology, supporting the efficacy 
of changes of dietary habits in priming specific metabolic pathways 
to better prepare animals to significant challenges. In this respect, 
the dietary behaviour of the semipalmated sandpiper (Calidris 
pusilla) before autumn migration is extraordinary. In preparation 
for the long flight from Canada to South America, this shorebird is 
able to enhance the energy efficiency of its wing muscles by acutely 
changing its diet and thus eating almost exclusively omega-3 rich 
mud shrimps.30 During the last centuries, human beings have lost 
their ability of selecting specific foods to better fight disease, but it is 
now possible to start considering the metabolic profile of the patients 
as a criterion according to which specific lipid emulsions should be 
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prescribed. Trauma is associated with an inflammatory response 
which is necessary to trigger the immune response. An exaggerated 
inflammatory response may increase the risk for complications, 
delayed recovery and even increased mortality. However, excessive 
inhibition of the inflammatory response via pharmacological or 
nutritional means may be equally detrimental. Indeed, Namas et al 
have recently demonstrated in trauma/haemorrhage patients that 
an adequately robust early inflammatory response is a hallmark of 
survival.18
It is therefore advisable that in clinical practice, lipid emulsions 
should not be considered as interchangeable and their metabolic 
effects should be taken into consideration. In patients in whom a 
robust inflammatory response is desirable, omega-6 fatty acids may 
be preferred. In clinical conditions where attenuation of inflammatory 
response is clinically meaningful, then omega-3 fatty acids should 
be considered. When perturbation of the physiologic inflammatory 
and immune response and/or exacerbation of oxidative stress could 
be associated with increased risk of complications, then omega-9 
fatty acids may be preferred.
Based on our better knowledge on the metabolic effects of lipid 
emulsions, it is now tempting to speculate their use as “drugs” could 
provide an adequate amount of immuno-modulating fatty acids on 
top of the calculated energy needs. In this context, omega-9 fatty 
acids could be provided as the energy source because of their 
“immuno-neutrality”, while omega-3 and omega-6 fatty acids could 
be provided as metabolic modulators. It is acknowledged that the 
available literature cannot yet support this approach, but it can also 
not be denied that such an approach would favourably exploit the 
potential clinical benefit of lipid emulsions. While waiting for clinical 
trials addressing the feasibility and relevance of this approach, it is 
important to be reminded that in matters concerning lipid emulsions 
“one size may not fit all (patients)”.
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